Greenphire Launches GreenSpace App
Greenphire has unveiled a new patient-facing digital platform, GreenSpace.
GreenSpace offers a unified digital experience accessible via iOS and Android devices, or through an internet browser. The platform provides access to trial-related information and activities such as financial views and account details, submission of receipts for reimbursement, visit and travel itinerary details, delivery of surveys and insights, and more.
In addition to GreenSpace, Greenphire has also expanded its payment offerings available through ClinCard. The solution will offer a suite of payment modalities for both banked and unbanked study populations. This provides patients with the ability to choose from options that best align with their personal needs, including reloadable debit cards, virtual cards, digital wallets, email to money and bank transfers that are real-time, low cost to customers, and zero fees for patients.
Reference
Greenphire Launches GreenSpace App and Expands Global Payment Functionality. (2023, April 25). Cision PR Newsire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
